Arecor Therapeutics (AREC LN)

Analysis

Health Care • United Kingdom

Arecor Therapeutics PLC is a clinical-stage biopharmaceutical company focused on developing superior therapeutics to address unmet patient needs in diabetes, obesity, and other cardiometabolic diseases. The company utilizes its proprietary Arestat® formulation technology platform to create enhanced reformulations of therapeutic products and to develop a portfolio of proprietary products, including AT278, an ultra-rapid acting insulin. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, United Kingdom.

Refresh

Exchange Announcement • 15 Oct 2026 13:00

Patents for concentrated ultra-rapid insulins

Exchange Announcement • 13 Oct 2026 16:39

Holding(s) in Company

Exchange Announcement • 13 Oct 2026 16:38

Holding(s) in Company

Exchange Announcement • 08 Oct 2026 18:56

Half Year Results Investor Presentation

Exchange Announcement • 08 Oct 2026 17:10

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00